# Apraglutide PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/apraglutide

> Apraglutide, sponsored by IRONWOOD PHARMACEUTICALS INC (IRWD): 3 recorded catalysts.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | apraglutide |
| Codes |  |
| Sponsor | IRONWOOD PHARMACEUTICALS INC (IRWD) https://sec-api.dev/companies/irwd/catalysts |
| Indications |  |
| Modality | peptide |
| FDA designations | orphan |

## Timeline

### Feb 2024: topline data readout

- Status: completed, positive. Date confidence: month. Stage: 3.
- First seen 2025-05-12, last confirmed 2025-05-12.
- SEC Form 10-Q (accession 0001558370-25-007406): "In February 2024, we announced positive topline results from our pivotal Phase III clinical" https://www.sec.gov/Archives/edgar/data/1446847/000155837025007406/irwd-20250331x10q.htm

### Q3 2025: NDA/BLA submission

- Status: scheduled. Date confidence: quarter.
- First seen 2025-02-27, last confirmed 2025-02-27.
- Press release filed with the SEC (EX-99) (accession 0001104659-25-017774): "- Initiated rolling NDA submission; on track to be completed in Q3 2025 -" https://www.sec.gov/Archives/edgar/data/1446847/000110465925017774/tm257621d1_ex99-1.htm

### Q2 2026: trial start

- Status: scheduled. Date confidence: quarter. Stage: 3.
- First seen 2025-08-07, last confirmed 2026-05-07.
- Press release filed with the SEC (EX-99) (accession 0001104659-26-056656): "- On track to begin site initiations for Phase 3 confirmatory trial of apraglutide in short bowel syndrome with intestinal failure (SBS-IF) in the second quarter of 2026 -" https://www.sec.gov/Archives/edgar/data/1446847/000110465926056656/tm267094d1_ex99-1.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-25-074972): "Pending alignment with the FDA, Ironwood expects to initiate a confirmatory Phase 3 trial in the first half of 2026." https://www.sec.gov/Archives/edgar/data/1446847/000110465925074972/tm2522671d1_ex99-1.htm

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/apraglutide.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Apraglutide PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/apraglutide

```bibtex
@misc{secapidev_pdufa_apraglutide_20261116,
  title        = {Apraglutide PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/apraglutide}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_apraglutide_20261116","title":"Apraglutide PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/apraglutide","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
